Introduction cells required (10 g of CHO cells for 10-20 tests) to purify The use of cancer cells expressing cytokines as vaccines sufficient B7.1-GPI coupled with problematic batch for immune gene therapy of cancer is already a reality, quality 2 make this a difficult system to use. and subject to a number of clinical trials. 1 The costimuLooking at the available alternatives, we observed that lators B7.1 and B7.2 in an allogeneic setting offer exciting in the mouse system ascitic fluid of a hamster IgG antipossibilities and have entered the clinic on a trial basis. 1 mouse CD28 antibody (clone 37.51) was capable of delay-B7.1 treatment in autologous protocols has yet to reach ing the growth of a murine K1735 melanoma cell chalthe trial stage. Reasons for this are multifarious, but lenge even when the two were injected into different include access to sufficient tumour cells and inefficiency locations at different time-points. 6 It is tempting to specuof the currently available gene transfer and expression late on the result had the two been injected together, or procedures.
the antibody somehow associated with the cells long It has become clear that a number of laboratories are enough for the potentially reactive T cells to receive both approaching the problem from the different and exciting T cell receptor/antigen MHC-mediated cross-linking as perspective of modifying cells ex vivo by nongenetic well as the CD28 mediated co-stimulatory signals. We means such that the cells express the genes of interest have investigated strategies for the association of antiwithout the requirement for genetic modification. [2] [3] [4] [5] The body with tumour cells in vitro such that they remain B7.1 gene has been engineered as a fusion protein, with closely associated and retain antibody function. Commereither the CD16B transmembrane domain 2 or sequences cially available reagents can be used to biotinylate cell from decay-accelerating factor (DAF), [3] [4] [5] which are subsurface proteins. Furthermore, an avidin bridge 7 in consequently glycosyl-phosphatidylinositol (GPI)-modified junction with protein G′-biotin 8 can effectively couple an within the cells to acquire a 'GPI anchor'. Purification of antibody such as mouse anti-human CD28 in an orienthis protein/GPI species allows the complex as a whole tation-specific manner. This should then allow the antito be applied to cells in such a way that the GPI portion body to remain associated with the cell long enough to of the molecule incorporates into the cell membrane and allow the activation of the target T cells and to provide the necessary co-stimulatory signal for the functional acti-difference was apparent in autofluorescence (Figures 3a,
Results
b, k and l), in the binding of secondary antibody (e, f, i Figure 1 shows a schematic representation of the steps and j, asterisks), the immunodetection of adhesion prodescribed in tein ICAM-1 (e and f) or the detection of MHC class I expression (i and j). This is in contrast to the effect seen Conjugation of mouse TIB232 cells with on the detection of a transfected and expressed mouse biotinamidocaproate N-hydroxysuccinimide ester B7.1 (CD80) protein where detectable surface expression Exposed NH 2 groups on cell surface proteins (primarily drops to half the normal level after biotinylation (Figure side groups of lysine) are readily biotinylated by suc3g compared with h, mean fluorescence index: MFI = 72 cinimide ester derivatives. 9 Incubation of mouse AKR and 31, respectively). Levels return to near normal after thymoma, TIB232 cells with 2.75 mm biotinamidocapro-24 h in culture (Figure 3o and p, MFI = 76 and 58, ate N-hydroxysuccinimide ester routinely resulted in a 2-respectively). log increase in FITC fluorescence, as measured by streptavidin-FITC immunofluoresence, compared to untreated Biotinylated cells can bind streptavidin cells. However the immunofluoresence on these cells rapBiotinylated cells can be incubated with high concenidly declined and by 72 h there was no more than a threetrations of streptavidin in such a way that the tetrameric fold difference (Figure 2a compared with b, i compared structure of streptavidin allows the molecule to both stick with j; see also Figure 8 ). This decay was not seen when to the cell surface and still retain active sites for the cells were in the presence of 0.05% sodium azide;
further binding of biotin-FITC. This is demonstrated in approximately a greater than 1-log difference remaining . This is 50% of cells in sodium azide were dead; 0.1% azide was mirrored by their increasing affinity for biotin-FITC found to be even more toxic whilst 0.01% was only (Figure 4b-j) . Surprisingly even at the highest concenmarginally. Sodium azide was therefore not used in tration of streptavidin, little nonspecific binding is seen, subsequent studies.
as determined by the inability of nonbiotinylated cells incubated with 160 g/ml streptavidin to bind either Biotinylation of cell surface proteins changes the biotin-FITC (Figure 4i ) or streptavidin-FITC (Figure 4k ). immunological profile of the cells Thus, cells can be treated in such a way that enables them Biotinylation has variable effects on the immunological to bind biotinylated proteins, though once the avidin is profile of B7.1 transfected TIB232 cells (Figure 3) . No bound it is no longer detected after 24 h in culture (DMEM + 10% FCS, no biotin in DMEM) data not shown.
Cells labelled with avidin can bind biotinylated antibody
We wished to determine whether cells once biotinylated and incubated with avidin can retain an anchor of active avidin in such a way that biotinylated antibody can then be bound to the cell surface via the avidin-biotin bridge. This was investigated using a biotinylated antibody (mouse anti-human HLA-DR) to bind to the avidin on the cell which we then detected with a FITC-conjugated F(ab′) 2 fragment of rabbit anti-mouse immunoglobulins. This is demonstrated in Figure 5 where as controls we show that untreated ( Figure 5a ) and biotinylated ( Figure  5b ) cells bind little FITC-conjugated F(ab′) 2 fragment of rabbit anti-mouse immunoglobulins. Untreated but avidin incubated cells (Figure 5c ) bind little biotin-FITC compared with biotinylated cells which have been incubated with avidin ( Figure 5d ) indicating both the attachment of avidin, via the biotin on the cell surface, and its ability to bind further biotin in the form of biotin-FITC. Untreated avidin-incubated cells (Figure 5e ) also bind little FITC-conjugated F(ab′) 2 fragment of rabbit antimouse immunoglobulins, but biotinylated cells (after incubation with avidin) (Figure 5f ) were found to bind substantially more (four-to five-fold increase in globulins as (Figure 5a and e), whilst biotinylated avidin incubated cells with biotinylated mouse anti-human a way that the variable region is exposed. We thus turned to a method of providing a more orientation-specific tech-HLA-DR (Figure 5h ) bind 10-fold more FITC-conjugated F(ab′) 2 fragment of rabbit anti-mouse immunoglobulins nique using the Fc binding properties of Streptococcus protein G leaving variable regions exposed. than the same cells in the absence of biotinylated mouse anti-human HLA-DR (Figure 5f ). Additional data not shown demonstrated that identical but nonbiotinylated Cells with bridged avidin can be used to assemble a complex with protein G′-biotin and antibody mouse anti-human HLA-DR does not bind nonspecifically to biotinylated avidin-treated cells, indicating that A more orientation specific antibody binding can be achieved with protein G′-biotin ( Figure 6 ). Thus poor orienthe binding of mouse anti-human HLA-DR to avidincoated cells was on the basis of the antibody-biotin contation interference with antibody function can be avoided, and antibody need not be biotin-conjugated. Cells jugate. Thus biotinylated antibody can be bound to the cell surface by an avidin bridge, and detected on the basis that were biotinylated and then cultured overnight were avidin-treated as described and incubated with protein of a species-specific constant region indicating that steric hinderance as a result of tight binding to avidin does not G′-biotin/mouse anti-human CD28 activating antibody 10 complexes. Figure 6 shows that after biotinylation, incutotally abrogate further antibody binding.
However, biotinylation of antibody is directed ranbation with avidin allows biotin-FITC to detect avidin on the surface of only the biotinylated cells ( Figure 6b ) and domly against NH 2 termini and lysine NH 2 side groups. Thus at least some of the antibody will not be bound in not untreated (nonbiotinylated) cells (Figure 6a ). The 
aliquots of either untreated (DMSO alone) (a, c, e, g, i, k, m and o) or biotinylated (b, d, f, h, j, l, n and p) cells were analysed for immunofluoresence as described (a-j) or were analysed after 24 h in culture (k-p). Cells were either unstained (a, b, k and l), streptavidin-FITC incubated (c, d, m and n), stained with ICAM-1 followed by rabbit anti-rat FITC or secondary alone (*) (e and f), FITC conjugated anti-mouse CD80 (B7-1) antibody (g, h, o and p) or anti-MHC H-2 class 1 (H-2 b,k,s,p ) followed by FITC-conjugated F(ab′) 2 fragment of rabbit anti-mouse immunoglobulins (i and j) or secondary alone (*) as described and analyzed by FACS.
presence of avidin on the surface then serves as a is less than 10% of that seen with additional CD28 (Figure  6k ), data not shown. target/anchor for protein G′-biotin-anti-CD28 complexes, the presence of which are detected after incubation with rabbit anti-mouse immunoglobulins F(ab′) 2 Stability of the complex When cells are returned to culture after avidin treatment, FITC. Cells that were biotinylated, avidin-incubated and then further incubated with the protein G′-biotin-CD28 either at 37°C or 4°C, over a period of 3.5 and 6 h the background staining of untreated (nonbiotinylated) cells complex (Figure 6k ), show almost a 2-log shift increase in fluorescence over the staining with nonbiotinylated cells treated with avidin and stained with biotin-FITC remains constant (compare Figure 6 (a, T = 0) with c, 3.5 h and f, ( Figure 6 , compare k with j). These staining profiles indicate that the entire complex (biotin-avidin-protein G′-6 h), duplicate cells which were kept at 0°C were identical to those kept at 37°C and therefore not included. Howbiotin-anti-CD28) can be assembled in a way predictable from the individual capabilities of the component parts.
ever when biotinylated cells were avidin-incubated and then immediately stained with biotin-FITC ( Figure 6b ) Nonspecific staining by rabbit anti-mouse immunoglobulins F(ab′) 2 -FITC of biotinylated cells treated with avidin the initial fluorescence decreased substantially when the cells were retested after 3.5 h at 4°C (Figure 6d ) but little and protein G′-biotin is also seen (see also Figure 5f ), but Having demonstrated colocalization of the mouse antihuman CD28 with target cells, we then tested the stimu6i). The temperature dependence of the change coupled with the retention of stain on biotin-FITC-labelled cells latory ability of bound protein G′-biotin/antibody in a functional assay for CD28-mediated stimulation of T in culture suggests that disappearance of the avidin is at least in part due to endocytosis of the cell membrane cells. TIB232 cells were complexed as described in the legend to Figure 7 , with appropriate controls. Once associated complex.
The entire avidin-protein G′-biotin-anti-CD28 complex assembled these cells were co-cultured with human Jurkat T cells. These cells possess both the CD28 receptor on biotinylated cells (Figure 6k ) again shows deterioration at 4°C over the first 3.5 h (Figure 6m ) with less and the CD3 complex and respond to stimulation via CD3 with PHA, or protein kinase C activation with PMA, change over the subsequent 2.5 h (Figure 6p ). Once again the background at 37°C (Figure 6l by secreting small amounts of IL-2 into the medium.
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Combinations of anti-CD28 with PHA or PMA synergistiremains the same and identical to the background seen at 4°C (data not shown). At 37°C (Figure 6n, 3 .5 h and cally increase the level of IL-2 secretion. Figure 7 shows that Jurkat cells in the absence of stimulation secrete little Figure 6q , 6 h) the complex deteriorates over the entire time-course, but remains above background even after detectable IL-2 either in the absence of TIB232 cells or with any of the modifications except biotin + avidin + 6 h (comparing Figure 6q with o) ; whilst stained cells line is the product of its CD28 activation by the anti-CD28 antibody bound to the TIB232 cells. Figure 8 demonstrates that the presence of antibody per se on the TIB232 cells does not allow them to activate Jurkat cells. Thus whilst anti-CD28 (B/AV/PG/CD28) costimulates with either PMA or PHA, anti-CD3 (B/AV/PG/CD3) costimulates only with PMA, and an isotype-matched but irrelevant antibody (CD14) that does not bind to Jurkat cells (unpublished results) (B/AV/PG/CD14) is unable to costimulate under any of the conditions tested. TIB232 cells that were biotinylated but not avidin-treated failed to bind protein G′-biotin and anti-CD28 (B+PG/CD28) and thus showed little costimulatory activity.
Biotinylation of cell membranes is not limited to murine cell lines
In order for this to be in any way applicable to treatment, primary human cells must be capable of responding to biotinylation in the same way as the cell lines so far tested. Figure 9 demonstrates that two primary AML patient samples (KR and TC) can both be kept in culture and biotinylated. In fact all cells tested so far are easily biotinylated, including murine myeloid 32Dp210 cells as well as human myeloid HL-60, U937, NB4 and K562 cells. be manufactured for this strategy to be used in therapy.
as described.
Although similar approaches have been reported, 12, 13 we believe that this is the first report of the use of an activating antibody attached to a tumour cell in such a way that the active site of the antibody is not involved protein G′-biotin + anti-CD28 (B/AV/PG/CD28). Jurkat cells incubated with PMA alone show little IL-2 secretion, in the initial binding. The orientation of the bound antibody is such that its antigen-binding variable region is and other conditions show no significant change until, once again, the PMA-treated cells are incubated with available for further interactions. The presented data show that cells can be readily biotinylated to a high level B/AV/PG/CD28. Under these conditions the stimuli appear synergistic. A surprising result is seen when the under conditions that are not toxic to the cells (data not shown). The biotin on the cell surface is progressively cells are stimulated with PHA. Here we see that both B/AV/PG/CD28 and control + avidin + protein G′-biotin lost, but this can be slowed down with the use of metabolic inhibitors. Since the initial efficiency of biotinylation + anti-CD28 (C/AV/PG/CD28) both synergise with PHA treatment of Jurkat cells. This is a reproducible phenomis high, the rate of reduction even in the absence of metabolic inhibitors can be tolerated as even after 72 h in culenon, and odd since neither avidin or protein G′-biotin bind nonspecifically to a sufficient degree to anchor antiture the presence of biotin on the cell surface can be readily detected. CD28 to these cells as determined by FACS analysis. We can only conclude that firstly the threshold of synergistic
We have demonstrated that potentially important surface proteins are targets for biotinylation, but not univerinteraction with CD28 and PMA is higher (ie less sensitive) than for PHA, and that the bioassay of the Jursally, so whilst the immunological profile of B7.1 on cells is altered this is not the case with CD54 (ICAM-1) or the kat cells detects lower levels of presented anti-CD28 than the FACS analysis. Finally the addition of anti-CD28 MHC class 1 on TIB232 cells. Additionally, after 24 h in culture the profile of detectable B7.1 returns to near noralone has little effect on the Jurkat cells, and the addition of more, with B/AV/PG/CD28, is not effective. Incumal levels. Putative tumour antigens may be targets for biotinylation and this may then destroy their immunobation of cells with anti-CD28 alone (control/anti-CD28, C/CD28) therefore does not allow this antibody to persist genicity, but we feel that it would be unlikely that biotinylation would interfere with all of them, and that fresh through the washing steps before the assay, neither does the presence of avidin and protein G′-biotin (B/AV/PG), product would not be re-expressed with additional culture. This has been shown to be the case with the only without the anti-CD28 to stimulate IL-2 production in these cells. Therefore these results strengthen the suggessurface marker found to be interfered with in our studies (ie B7.1). tion that the stimulation of IL-2 production by the T cell 
ml on ice were incubated with 6 l of biotinamidocaproate N-hydroxysuccinimide ester as described, washed twice in RPMI + 10% FCS and cultured at 37°C overnight. After 18 h, 2.4 × 10 7 biotinylated cells (b, d, e, g, h, i, k, m, n, p, q and r) and untreated equivalents (a, c, f, j, l and o) were avidin treated as described, after which cells were washed twice in HBSS + 1% FCS, resuspended in 300 l of HBSS + 1% FCS, 100 l aliquots (8 × 10 6 each) were then added either to carrier alone (a-i) or a preformed complex of 42 g mouse anti-human CD28 + 8.5 g protein G′-biotin (j-r). After a further 30 min, cells were washed twice in DMEM + 10% FCS (DMEM is deficient in biotin), and a sample taken immediately for staining and FACS analysis as described (T = 0 time-point, a, b, j and k), the remaining cells were divided into two and cultured either at 37°C for 3.5 h (c, e, l and n) and 6 h (f, h, o and q) or 4°C for 3.5 h (d and m) or 6 h (g and p) harvested and stained for FACS analysis. (i and r) Duplicates of b and k that were returned to culture after staining and incubated for a further 6 h at 37°C. Before processing the biotinylation efficiency was checked and found to have worked as normal (data not shown). All samples stained as indicated on the Figure and analyzed by FACS as described.

Once the cells have been labelled with biotin, either
Biotinylated antibody binds with avidin-treated biotinylated cells in a way that was predictable from the nature avidin or streptavidin can be used to provide a bridge to other reagents. One initial worry was that the stoichiof biotinylated antibody. However the orientation of these antibodies on the cell surface is not predictable. The ometry of the avidin treatment, despite the tetrameric nature of the protein, would result in the inactivation of conjugation reaction to biotinylate antibody was performed using its succinimide ester derivative, and does not further biotin-binding activity of the bridge. We find that as long as the streptavidin/avidin concentration is suftarget constant regions, but reacts with lysine NH 2 side groups. 9 Since biotin labelling procedures for antibody ficiently high this is not a problem. some bound antibody would be correctly orientated. A more directed strategy was utilized where the orientation of the bound antibody was more predictable. This length of time that the complex would need to remain for the strategy to be truly effective as a cell vaccine. A was done because the gift of the mouse anti-human CD28 was valuable and in relatively short supply (we wished number of antibody combinations and cytokines are currently being examined in animal models in order to to avoid an antibody-biotin conjugation reaction) and the alternative strategy provides added flexibility to the determine this. Although low temperature and azide appear to be able to inhibit degradation to a certain potential user.
Conditions were either Jurkat cells alone (no addition), biotinyldescribed. Conditions were either Jurkat cells alone, untreated (control) ated cells, no avidin, with protein G′-biotin + anti-CD28 (B + PG/CD28), cells incubated with mouse anti-CD28 (C/CD28), untreated (control) cells biotinylated cells incubated with avidin + protein G′-biotin + anti-CD28 incubated with avidin + protein G′-biotin + anti-CD28 (C/AV/PG/CD28), (B/AV + PG/CD28), biotinylated cells incubated with avidin + protein G′-biotinylated cells incubated with avidin + protein G′-biotin + anti-CD28 biotin + anti-CD3 (B/AV + PG/CD3), and finally biotinylated cells incu-(B/AV/PG/CD28) or biotinylated cells incubated with avidin and protein bated with avidin + protein G′-biotin + anti-CD14 (B/AV + PG/CD14). G′-biotin alone (B/AV/PG). The human IL-2 ELISA detects human IL-2 The human IL-2 ELISA detects human IL-2 alone, and does not crossalone, and does not cross-react with recombinant murine IL-2 in our hands react with recombinant murine IL-2 in our hands (data not shown). Data (data not shown). Data points show the pg/ml of quadruplicate determipoints show the pg/ml of triplicate determinations of IL-2 (±1 standard nations of IL-2 (±1 standard deviation). deviation). Crossed bars represent those samples whose IL-2 concentration
Since we were not actually cross-linking in this study degree neither of them can be used in vivo, thus alternative strategies are at present under investigation. we were somewhat surprised that the avidin protein G′-biotin complex once assembled on the cell surface disapOther labelling strategies have been utilized to simplify the system as much as possible and reduce the size of the pears quite rapidly. At least one major component of this deterioration involved the internalization of the complex complex on the cell surface. One of the first, that proved ultimately fruitless, was to avoid the biotinylation cominto the cell, presumably by endocytosis. This process appears to be stimulated by the addition of more compopletely and avidinylate the cells directly with the commercially available maleimide and hydrazide derivatives nents to the cell membrane, given that the decrease in biotin level on the cells takes place over a period of days, of avidin. The problem with these was that the pretreatment required to optimize the presence of the correct tarwhilst avidin complexed to the cells deteriorates in hours. Even with the rapid deterioration however, a detectable gets (SH groups for the maleimide 13 and modified cell surface glycoprotein for the hydrazide 15, 16 ), were in our amount remains after 6 h in culture, and sufficient remains attached, even after extensive washing of the hands quite cytotoxic and the labelling not very efficient.
The high molecular weight of avidin compared with cells, for anti-CD28 to be used in the Jurkat costimulation assay.
biotin also precluded the application of sufficiently high molar concentrations of derivatised avidin. Other We have not yet investigated whether an in vitro effect can be seen with tumour and effector cells from a reagents such as the N-(biotinoyl) dipalmitoyl-l-␣-phosphatidylethanolamine (biotin-DPPE 12 ) conjugate was tumour-bearing patient. It is of course quite possible that the presence of anti-CD28 alone in this case would not capable of only minimal association with the membrane and was very unstable. Synthesis of biotinylated cationic be sufficient, because the tumour specific T cells may be in the anergic state. In addition little is known about the lipidophiles such as 1,1′-didodecyl-,3,3′,3′-tetramethyl-by (2) application of a commercially available reagent comprising the antibody (or antibody-avidin conjugate) of choice complexed with streptavidin-avidin-protein A/G at the optimal molar ratio. Finally it has been shown that some recombinant single chain Fv species whilst retaining affinity have reduced avidity for antigen due to their monomeric structure. This can be reversed in some cases by a single chain Fv-core/streptavidin fusion protein. 22 The, streptavidin mediated, tetrameric structure of the molecule can enhance the avidity of the Fv. Recombinant single chain Fvs of anti-CD28 (9.3) may not initially look like a good choice as a Fab fragment of anti-CD28 (9.
3) does not demonstrate costimulatory activity whilst a F(ab′) 2 fragment of the same antibody is as active as the whole molecule. 23 This may not be due to lack of avidity as this Fab fragment can compete quite effectively with native B7.1 in blockade of CD28 pathway-dependent proliferation of ICAM-1-primed T cells. 24 It is of obvious interest to determine whether Fv (9.3) fusions with streptavidin would reactivate costimulatory activity. Such a fusion protein would, if active, combine the ability to express large amounts of a recombinant Fv that retains therapy.
indocarbocyanine perchlorate (DiI) of the indocarbo-
Materials and methods
cyanine family, which are often used as membrane probes 17 and may ultimately be the reagent of choice, are Monoclonal antibodies apparently very difficult to synthesize.
The following antibodies were used: mouse antibody Any antibody (either biotinylated or not) and any pro-9.3 10 (IgG2a) recognizing human CD28 (1 mg/ml in PBS), tein (of those that can be biotinylated) can be anchored was a generous gift from Dr Karl Hellströ m at Bristolto the cell surface and this will allow the rapid evaluation Myers Squibb, Seattle, WA, USA; mouse antibody (IgG2a, of combinations of potential immune costimulators/supclone HIT3a) recognizing human CD3, 0.5 mg/ml in 150 pressors in in vivo mouse models. Thus cells lacking mm NaCl (Pharmingen, San Diego, CA, USA; 30111A); adhesion molecules can be labelled transiently with the mouse antibody (IgG2a, clone M5E2) recognizing human adhesion molecule to allow the costimulation. A slow CD14, 0.5 mg/ml in 150 mm NaCl (Pharmingen 30541A); release capability for cytokines may be feasible by the biotin-conjugated mouse (IgG2a) anti-human HLA-DR, careful choice of linker groups in the complex introducand identical nonbiotinylated antibody, both 25 g/ml ing protease-sensitive sites. Questions such as the relative (Becton Dickinson, Mountain View, CA, USA; 347361 and efficacy of an anti-CD28 antibody and the natural counter 347360 respectively); FITC-conjugated hamster antireceptor for CD28 (B7.1 which can provide an inhibitory mouse CD80 (B7-1), IgG 0.5 mg/ml used at 1:20 dilution signal to T cells expressing CTLA4 18, 19 ), and novel combi-(Pharmingen 09604D); rat (IgG2a) anti-mouse CD54 nations such as anti-CD28, with either anti-CD3 or anti-(ICAM-1), 1 mg/ml used at 1:10 dilution (Serotec, CD2, 20 can be more rapidly assessed. Oxford, UK; MCA818); mouse (IgG2) anti-mouse MHC We are presently looking at ways of stabilizing the H-2 class 1 (H-2 b,k,s,p , 1 mg/ml used at 1:10 dilution complex we have so far designed and animal experi-(Biodesign, Kennenbunk, USA; M4918M). ments with the avidin/biotinylated antibody are in progress. We feel that the ability to modify large numbers of tumour cells ex vivo in a very short time may be more Cells Mouse AKR1.G.1.OUAR.1.26, 25 AKR strain-specific thyadvantageous (even with the lack of stability) than more difficult nucleic acid-based procedures. moma cell line was obtained from the ATCC Tumour Immunology Bank, Rockville, MD, USA, hereafter The strategy may ultimately be further simplified using an E. coli expressable chimeric streptavidin-protein A referred to as TIB232, and grown routinely in RPMI + 10% FCS, 2 mm l-glutamine, 100 g/ml streptomycin, molecule. 21 This could allow the whole process to be simplified to a two-step reaction: (1) biotinylation, followed 100 U/ml penicillin between 5 × 10 TIB232 B7.1 clone 2, cells were grown as above and with PBS pH 8.0 in the absence of serum, and resuspended in 400-800 l of ice-cold PBS pH 8.0 to the indiretrovirally infected with supernatant from the packaging cell PA317MB7.1 Hygro. Briefly PA317MB7.1 Hygro was cated cell concentration (see Figure legends) , transferred to a fresh polypropylene tube and placed on ice. To a dry the result of a supernatant infection from GP + E86 cells transfected with the retroviral vector plasmid M 3 PHyportion of the side of the tube 3-6 l of 366 mm biotinamidocaproate N-hydroxysuccinimide ester in DMSO was gro 26 into which had been cloned the murine B7.1 gene under the control of the long terminal repeat (LTR) of the added and the tube flicked to dilute quickly (reversing the order of the addition resulted in crystallization of the vector. Supernatant from a clone of PA317 cells that were positive by FACS for the mouse B7.1 gene (data not reagent), the cells were then immediately returned to ice and incubated for 30 min with periodic gentle agitation. shown) was taken and used to infect TIB232 cells with eight rounds of supernatant infection and were then Cells were then washed twice in RPMI + 10% FCS and returned to culture in RPMI + 10% FCS overnight at 37°C, selected in 400 U/ml hygromycin B. Resistant cells were cloned by limiting dilution. TIB232 B7.1 clone 2 was or immediately assessed for biotinylation efficiency as described under immunofluoresence. chosen as a representative B7.1 positive clone (see Figure  3g compared with a) and used for the determination of For streptavidin or avidin treatment, biotinylated cells were cultured overnight, counted, and 1-8 × 10 7 cells the effect of biotinylation on immunological profile.
Human Jurkat JH6.2 11 cells were a kind gift from Dr were washed twice with HBSS + 1% FCS and resuspended in HBSS + 1% FCS in the presence or absence D Cantrell, Lymphocyte Activation Laboratory, Imperial Cancer Research Fund, London, UK. They were recloned of avidin (usually at 1 mg/ml, unless otherwise stated), incubated for 30 min on ice, and washed twice in ice-cold and colonies screened by FACS analysis for CD3 expression. Clone 5 expressed the highest levels of CD3 HBSS + 1% FCS and either analyzed by FACS as described under immunofluoresence below, or further and was used subsequently in the study. Cells were grown in RPMI + 10% FCS, 2 mm l-glutamine, 100 g/ml processed. For binding of biotinylated antibody to modified cells, streptomycin, 100 U/ml penicillin, regularly rechecked for CD3 expression and discarded after more than cells were biotinylated and avidin-treated (as described above) and incubated in 100 l of HBSS + 1% FCS/1 × 10 6 1 month in culture. Primary human acute myeloid leukaemia (AML) cells cells in the presence of 0.5 g of biotin-conjugated mouse IgG2a anti-human HLA-DR, or identical nonbiotinylated were collected by leucapheresis, and mononuclear cells obtained by density gradient separation (Ficoll-Hypaque; antibody, incubated on ice for 30 min and washed twice in HBSS + 1% FCS. Any bound antibody was detected as Pharmacia Biotech) and cryopreserved in medium with 30% autologous serum and 10% DMSO. Cells for culture described under Immunofluoresence below. For protein G′-biotin/anti-human CD28, CD3 or CD14 were washed in medium after thawing and resuspended to between 5 × 10 6 and 1 × 10 7 /ml in Iscove's modified complexing, a 5:1 g ratio (Sigma, binding capacity 5 mg human IgG per milligramme protein G′ approximately) Eagle's medium (IMDM) with 100 g/ml streptomycin, 100 U/ml penicillin, 10% FCS (all from Sigma, Poole, of mouse anti-human CD28 antibody and protein G′-biotin was incubated on ice for 30 min. This complex was UK), 10 ng/ml recombinant human GM-CSF (kind gift from Schering-Plough, Bury St Edmunds, UK), 20 ng/ml then added to cells and incubated on ice for a further 30 min after which they were washed twice with HBSS + recombinant human stem cell factor (SCF) (225-SC, R&D Systems, Oxford, UK) and 10 ng/ml recombinant human 1% FCS and binding of the complex was detected as described under Immunofluoresence. Cells not for bind-IL-3 (kind gift from Sandoz Pharmaceuticals, Camberley, UK). Cells were pelleted each day and resuspended to ing determination were cultured in DMEM + 10% FCS (see Figure 1 for schematic representation of the above the above cell concentration. Under these conditions the two cell types KR and TC maintained 95% viability over treatments). 10 days (data not shown).
Immunofluoresence Reagents
For detection of cell surface conjugated biotin, cells Biotinamidocaproate N-hydroxysuccinimide ester (Sigma (5 × 10 5 ) were incubated in 100 l of HBSS/1% FCS con-B2643) reconstituted to 166.6 mg/ml (366 mm) in DMSO taining streptavidin-FITC at 1:100 dilution, left for 30 min and stored at −20°C, can be frozen and thawed numerous on ice, washed twice, resuspended in 0.5 ml of buffer and times whilst still retaining activity. Other reagents were analysed by flow cytometry. prepared as stock solutions, divided into aliquots and For detection of cell surface avidin-bound biotin, cells stored at −20°C: streptavidin (Sigma S8276) (1 mg/ml in (5 × 10 5 ) that bound avidin were assayed by incubating sterile water); avidin (Sigma A9390) (5 mg/ml in sterile the cells in 100 l HBSS/1% FCS containing biotin-FITC PBS pH 8.0); streptavidin-FITC (Sigma S3762) (0.5 mg/ml at 1:100 dilution, left for 30 min on ice, washed twice, in sterile PBS pH 8.0), used at 1:100 dilution; biotin-FITC resuspended in 0.5 ml of buffer and analysed by flow (Sigma B8889) (1 mg/ml in PBS pH 8.0), used at 1:100 cytometry. dilution; recombinant protein G′-biotin (Sigma P8045) (1 For immunodetection of cell surface molecules and of mg/ml in PBS pH 7.0); recombinant protein G′ (Sigma bound MAbs, cell surface detection of ICAM-1, MHC P4689) (1 mg/ml in PBS pH 7.0); phorbol myristate acetclass I or B7.1 was performed by incubating 5 × 10 5 cells ate (PMA) (Sigma P8139) (1 mg/ml in DMSO); PHA in 100 l HBSS/1% FCS containing the appropriate anti-(phytohaemagglutinin P, Pharmacia Biotech 27-3707) (10 bodies, left on ice for 30 min and washed twice in the mg/ml in water).
same buffer. For the immunodetection of bound MAbs, cells were incubated in 100 l of HBSS/1% FCS containBiotinylation and avidin bridging For biotinylation, cells in exponential phase were washed ing FITC-conjugated F(ab′) 2 fragment of rabbit antimouse immunoglobulins (Dakopatts, Glostrup, once with HBSS + 1% FCS at room temperature, and once
